Apogepha Arzneimittel (Germany)

Recent papers from Apogepha Arzneimittel (Germany)

1. Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patientsFrontiers in Pharmacology · 2023
2. The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment LandscapeCancers · 2022
3. Associations between the Patient Perception of Bladder Condition score and overactive bladder syndrome symptoms at baseline and upon treatmentNeurourology and Urodynamics · 2022
4. What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with PropiverineAdvances in Therapy · 2022
5. Factors Associated with Decisions for Initial Dosing, Up-Titration of Propiverine and Treatment Outcomes in Overactive Bladder Syndrome Patients in a Non-Interventional SettingJournal of Clinical Medicine · 2021
6. Do overactive bladder symptoms and their treatment‐associated changes exhibit a normal distribution? Implications for analysis and reportingNeurourology and Urodynamics · 2020
7. Results of a randomized, double‐blind, active‐controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladderBJU International · 2016
8. Influence of a Fat‐Rich Meal on Bioavailability of Extended‐Release and Immediate‐Release PropiverineThe Journal of Clinical Pharmacology · 2011
9. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort studyBJU International · 2009
10. Citric acid as a pH-modifying additive in an extended release pellet formulation containing a weakly basic drugDrug Development and Industrial Pharmacy · 2009
11. Disposition and Antimuscarinic Effects of the Urinary Bladder Spasmolytics Propiverine: Influence of Dosage Forms and Circadian‐Time RhythmsThe Journal of Clinical Pharmacology · 2008
12. Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysisBJU International · 2006
13. Pharmacodynamics of propiverine and three of its main metabolites on detrusor contractionBritish Journal of Pharmacology · 2005
14. Cholinergic and Purinergic Responses in Isolated Human Detrusor in Relation to AgeThe Journal of Urology · 2005
15. Effect of levothyroxine administration on intestinal P‐glycoprotein expression: Consequences for drug disposition*Clinical Pharmacology & Therapeutics · 2002
16. Increased surfactant protein D in rat airway goblet and Clara cells during ovalbumin‐induced allergic airway inflammationClinical & Experimental Allergy · 2002
17. Time versus frequency domain techniques for assessing baroreflex sensitivityJournal of Hypertension · 2001
18. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interactionClinical Pharmacology & Therapeutics · 2000
19. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil*Clinical Pharmacology & Therapeutics · 1999
20. New Aminocarboxamides with Class III Anti-Arrhythmic ActivityArchiv der Pharmazie · 1999